MingDe Lin, Ph.D.

Directing Clinical Research in Academic-Industry Partnerships

Ming is the Visage Imaging, Inc. Director of Clinical Research for North America and is stationed at the Yale-New Haven Hospital where he oversees, coordinates, drives and directs research collaborations with high profile academic hospitals in North America to develop new solutions for diagnostic image analysis and guidance that improve clinical and operational outcomes while reducing cost of care. This includes activities in Artificial Intelligence (AI) and Machine Learning (ML) in the Radiology enterprise diagnostic imaging solutions space. Ming identifies opportunities for academic-industry research partnerships, and acts as the liaison between Visage Imaging researchers and clinical collaborators to translate ideas to prototype for clinical validation, with the goal of technology transfer to product. A highlight is Ming coordinated the clinical data curation and ground-truth annotation for building a fully automatic breast density AI classifier that provides an ACR BI-RADS Atlas 5th Edition breast density category to aid radiologists in the assessment of breast tissue composition from full field digital mammography and digital breast tomosynthesis systems and drove the clinical validation with Yale radiologists and Visage developers that led to transfer to product and regulatory approvals in 21 months. Notably, this was the first for a major PACS vendor to offer a self-developed, FDA-cleared AI algorithm natively into their PACS: Visage Breast Density, K201411, 510(k) clearance, January 2021, Health Canada Licensed, October 2020, Australian TGA approval, July 2020, CE Mark Cleared, May 2020.
BD AI classifier

Dr. Lin also is directly involved in research to develop better ways to treat patients with liver cancer using
transcatheter arterial chemoembolization (TACE) and in this context, Ming is also the chief engineer and operations manager of the Yale Interventional Oncology Research Lab. Dr. Lin is the principal investigator for National Cancer Institute grants on this work titled Quantitative Multimodal Image Guidance for Improved Liver Cancer Treatment (R01 CA206180) and See, Reach, Treat Tumor - Optimized Transarterial Chemoembolization Drug Delivery (R01 CA160771). A highlight is the development of a 3D quantification method for improved response assessment after TACE called quantitative European Association for the Study of the Liver (qEASL). Ming's invention has been shown to be much improved over the current tumor viability measurement methods that are qualitative and 1- or 2-dimensional in being a more accurate match to pathology and in predicting patient survival sooner so that treatment decisions can be made earlier. Ming's prototype was validated and shown to have clinical value and transferred to be come a product that received FDA 510(k) approval.

Prior to Visage Imaging, Ming was the
Philips Healthcare research site manager and senior researcher stationed onsite at Yale where he managed the research portfolio and partnership Philips has with Yale. Ming obtained his Ph.D. in biomedical engineering at Duke University researching high resolution x-ray imaging for small animals. The research was conducted at the Duke Center for In-Vivo Microscopy.
3D quantitative therapy response assessment